Sunshine Biopharma Inc. (SBFM) Stock Forecast & Price Target
Price as of Nov 18, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Sunshine Biopharma Inc. (SBFM), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Sunshine Biopharma Inc., analysts forecast revenue rising from $21.03M in 2023 to $45.00M in 2027; the average estimate for 2027 earnings per share is −$8.00; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Sunshine Biopharma Inc. (SBFM) forecast — frequently asked questions
What are analysts forecasting for Sunshine Biopharma Inc.'s earnings?
The average analyst estimate for Sunshine Biopharma Inc. (SBFM) earnings per share in 2027 is -8.00, with individual estimates between -8.00 and -8.00.
How much revenue is Sunshine Biopharma Inc. expected to make?
Analysts forecast Sunshine Biopharma Inc. (SBFM) revenue of $45.00M in 2027, based on 1 published estimates.
How many analysts cover SBFM?
1 analyst contribute estimates for Sunshine Biopharma Inc. (SBFM). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - Specialty & Generic stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.